Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-positive Non Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01562015
What this trial is testing

Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
Synta Pharmaceuticals Corp. 12
Testing effectiveness (Phase 2)Study completedNCT01625234
What this trial is testing

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Who this might be right for
Advanced Solid TumorsNon-small Cell Lung Cancer
Xcovery Holdings, Inc. 131
Not applicableStudy completedNCT04087473
What this trial is testing

Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

Who this might be right for
Non-small Cell Lung CancerALK-Positive Lung Cancer
National Cancer Centre, Singapore 50
Testing effectiveness (Phase 2)Study completedNCT01970865
What this trial is testing

PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Who this might be right for
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Pfizer 364
Not applicableAvailableNCT04146571
What this trial is testing

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Who this might be right for
Non-Small Cell Lung CancerALK Gene Rearrangement Positive
Xcovery Holdings, Inc.
Post-approval studies (Phase 4)Not Yet RecruitingNCT07674368
What this trial is testing

Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed

Who this might be right for
ALK Fusion-positive Non-small Cell Lung Cancer
Hunan Cancer Hospital 29
Not applicableEnded earlyNCT02228421
What this trial is testing

Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer Metastatic
PeriPharm 29
Early research (Phase 1)Study completedNCT03607188
What this trial is testing

Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 17
Large-scale testing (Phase 3)Study completedNCT01639001
What this trial is testing

Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Pfizer 207
Large-scale testing (Phase 3)UnknownNCT04009317
What this trial is testing

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
ALK-positive NSCLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 260
Testing effectiveness (Phase 2)Active Not RecruitingNCT05491811
What this trial is testing

Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 47
Testing effectiveness (Phase 2)Ended earlyNCT03666728
What this trial is testing

SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Who this might be right for
Lung Neoplasms
Jiangsu HengRui Medicine Co., Ltd. 5
Not applicableUnknownNCT05991895
What this trial is testing

Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Jinming Yu 5,000
Early research (Phase 1)Study completedNCT03420742
What this trial is testing

Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

Who this might be right for
Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
Takeda 24
Not applicableStudy completedNCT03833934
What this trial is testing

Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance

Who this might be right for
Non-Small Cell Lung Cancer
Addario Lung Cancer Medical Institute 62
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Large-scale testing (Phase 3)Study completedNCT02737501
What this trial is testing

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

Who this might be right for
Non-small Cell Lung CancerLung CancerAdvanced Malignancies+1 more
Ariad Pharmaceuticals 275
Large-scale testing (Phase 3)Not Yet RecruitingNCT06254599
What this trial is testing

SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Shouyao Holdings (Beijing) Co. LTD 255
Testing effectiveness (Phase 2)UnknownNCT04056572
What this trial is testing

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
ALK-positive NSCLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 135
Not applicableStudy completedNCT03546894
What this trial is testing

Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Who this might be right for
Anaplastic Lymphoma Kinase-positiveCarcinoma Non-small-cell Lung
Takeda 111
Next Page